Fiagon, a medical technology company that develops and manufactures innovative surgical navigation systems, today announced a partnership with Entellus Medical, to be the exclusive distributor of Fiagon Image Guidance Systems (IGS) for ENT offices and ENT Ambulatory Surgery Centers across the United States.
Fiagon develops and manufactures innovative surgical navigation systems using the latest generation of proprietary "FlexSensor" electromagnetic based navigation technology. Together, the Entellus XprESS Pro balloon dilation system and the Fiagon image guidance system will provide ENT physicians greater confidence in device placement during ENT procedures.
Fiagon develops and manufactures innovative surgical navigation systems of the latest generation with its proprietary "FlexSensor" technology. In the last several years Fiagon, along with world-renowned physicians, has changed the standard in ENT navigation with its electromagnetic based navigation technology.
This unique technology is already being used in oral and maxillofacial surgery, neurosurgery and spine surgery, outside the U.S., mainly in Europe and Asia.
Entellus has led the way in moving balloon sinus dilation from the operating room to the physician’s office, providing proven equivalent results to traditional sinus surgery while delivering a superior patient experience.
The addition of image guidance in the office setting will continue to accelerate the OR to office setting shift, and also will deliver potential cost savings to patients and the healthcare system.
"The Fiagon system is uniquely suited for the office environment and we are excited to add this technology to our product portfolio," said Robert White, President and CEO of Entellus Medical.
"Our system has been designed with simplicity and ease of use in mind. The result is a system that is tailor-made for the physician’s office while providing the best possible accuracy, precision and confidence. The combination of the Entellus XprESS Pro and the Fiagon IGS is a win-win for physicians and patients," said Timo Kruger, CEO of Fiagon.